Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
8 January 2018 |
Main ID: |
EUCTR2014-002098-12-GB |
Date of registration:
|
30/03/2015 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Study of Multiple Doses of ISIS ISIS 396443 Delivered to Infants with
Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
|
Scientific title:
|
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy - NURTURE |
Date of first enrolment:
|
10/06/2015 |
Target sample size:
|
25 |
Recruitment status: |
Authorised-recruitment may be ongoing or finished |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-002098-12 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 1
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Australia
|
Germany
|
Italy
|
Qatar
|
Taiwan
|
Turkey
|
United Kingdom
|
United States
|
Contacts
|
Name:
|
Medical Director
|
Address:
|
Innovation House, 70 Norden Road
SL6 4AY
Maidenhead
United Kingdom |
Telephone:
|
|
Email:
|
clinicaltrials@biogen.com |
Affiliation:
|
Biogen |
|
Name:
|
Medical Director
|
Address:
|
Innovation House, 70 Norden Road
SL6 4AY
Maidenhead
United Kingdom |
Telephone:
|
|
Email:
|
clinicaltrials@biogen.com |
Affiliation:
|
Biogen |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Age = 6 weeks at first dose - Genetic documentation of 5q SMA homozygous gene deletion or mutation or compound heterozygous mutation. - Genetic documentation of 2 copies of survival motor neuron 2 (SMN2). - Ulnar Compound muscle action potential (CMAP) = 1 mV at Baseline. - Gestational age of 37 to 42 weeks for singleton births; gestational age of 34 to 42 weeks for twins. - Meet additional study related criteria. Are the trial subjects under 18? yes Number of subjects for this age range: 25 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range 0 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria: - Hypoxemia (oxygen saturation <96% awake or asleep without any supplemental oxygen or respiratory support). - Any clinical signs or symptoms at Screening or immediately prior to the first dosing (Day 1) that are, in the opinion of the Investigator, strongly suggestive of SMA. - Clinically significant abnormalities in hematology or clinical chemistry parameters. - Treatment with an investigational drug given for the treatment of SMA biological agent, or device. Any history of gene therapy, prior antisense oligonucleotide (ASO) treatment, or cell transplantation. - Meet additional study related criteria.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Spinal Muscular Atrophy (SMA) MedDRA version: 20.1
Level: PT
Classification code 10041582
Term: Spinal muscular atrophy
System Organ Class: 10010331 - Congenital, familial and genetic disorders
|
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
|
Intervention(s)
|
Trade Name: Spinraza Product Name: Spinraza Product Code: ISIS 396443 (BIIB058) Pharmaceutical Form: Solution for injection INN or Proposed INN: Nusinersen CAS Number: 1258984-36-9 Current Sponsor code: ISIS 396443 (BIIB058) Other descriptive name: ISIS 396443 (BIIB058) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2.4-
|
Primary Outcome(s)
|
Main Objective: The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA).
|
Timepoint(s) of evaluation of this end point: Up to Day 1820
|
Primary end point(s): Time to death or respiratory intervention. The time will be the age of the participant at the first occurrence of either a respiratory intervention or death. Respiratory intervention is defined as invasive or noninvasive ventilation for =6 hours/day continuously for 7 or more days OR tracheostomy.
|
Secondary Objective: Secondary objectives of this study are to examine the effects of Nusinersen in infants with genetically diagnosed and presymptomatic SMA.
|
Secondary Outcome(s)
|
Secondary end point(s): 1 Percentage of participants developing clinically manifested spinal muscular trophy(SMA) 2 Percentage of participants alive 3 Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE) 4 Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria 5 Change from Baseline in the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale 6 Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) 7 Change from Baseline in weight for age/length 8 Change from Baseline in head circumference 9 Change from Baseline in chest circumference ratio 10 Change from Baseline in head to chest circumference ratio 11 Change from Baseline in arm circumference ratio 12 Incidence of adverse events (AEs) and/or serious adverse events (SAEs). 13 Change from Baseline in clinical laboratory parameters 14 Change from Baseline in electrocardiograms (ECGs) 15 Change from Baseline in vital signs 16 Change from Baseline in neurological examinations 17 Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations
|
Timepoint(s) of evaluation of this end point: Points 1, 3 and 4 will be measured at 13 and 24 months of age Point 2 will be measured at 13 months, and 2, 3, 4 and 5 years of age Point 5 to 16 inclusive will be measured up to Day 1820 Point 17 will be measured up to Day 1730
|
Secondary ID(s)
|
232SM201
|
NCT02386553
|
2014-002098-12-IT
|
Source(s) of Monetary Support
|
Biogen Idec Research Limited
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|